A Test in Context: Lipoprotein(a) — Diagnosis, Prognosis, Controversies, and Emerging Therapies

Authors, Journal, Affiliations, Type, DOI

• Sotirios Tsimikas, MD
• Journal of the American College of Cardiology, Vol. 69, No. 6, 2017:692–711
• Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego; concurrent appointment at Ionis Pharmaceuticals
• Review article (Review Topic of the Week)
• DOI: https://doi.org/10.1016/j.jacc.2016.11.042

Overview

This foundational single-author JACC review by the leading Lp(a) investigator systematically covers Lp(a) structure, metabolism, CVD mechanisms, calcific aortic valve stenosis (CAVS) biology, clinical epidemiology, and nine areas of controversy including assay standardization, risk thresholds, racial differences, statin effects, and therapeutic interventions. Key quantitative contributions include ASTRONOMER trial data on faster aortic stenosis progression with elevated Lp(a) and OxPL-apoB, AIM-HIGH/JUPITER/LIPID meta-analysis (weighted HR 1.61 for residual MACE on statin), an individual-level analysis of 3,896 patients showing statins raise Lp(a) by mean 11% (OxPL-apoB +24%), and the mechanistic rationale for why >50% Lp(a) reduction is likely required for clinical benefit. The review foreshadows GalNAc-ASO development with IONIS-APO(a)-LRx achieving 66–92% Lp(a) reduction (up to 99%).

Keywords

Lipoprotein(a), apolipoprotein(a), oxidized phospholipids, calcific aortic valve stenosis, antisense oligonucleotides, cardiovascular risk, residual risk

Key Takeaways

Lp(a) Structure and Assembly

• Lp(a) = LDL-like lipid core with apoB-100 covalently linked to apolipoprotein(a) [apo(a)] via a single disulfide bond between KIV-9 of apo(a) and apoB; assembly site uncertain (hepatocyte/space of Disse/plasma compartment)
• Apo(a) evolved from the plasminogen gene through duplication (~3 million years); contains 10 KIV subtypes: KIV-1 and KIV-3–10 present in single copy, KIV-2 present in 1 to >40 copies — the source of extensive isoform heterogeneity (>40 isoforms, >40 particle sizes)

• 80% of individuals carry two different-sized apo(a) isoforms (one per parent); small isoforms → higher Lp(a) levels (higher molar production per unit time)

• Apo(a) has no lipid transport function; is hydrophilic; contains lysine-binding sites enabling accumulation in arterial endothelium and aortic valve leaflets
• Apo(a) contains an inactive protease domain — hence no enzyme activity; this constrains therapeutic approaches (cannot use small-molecule enzyme inhibitors)

Lp(a) Metabolism

• Circulating Lp(a) levels >90% genetically determined by the LPA gene locus; minimal dietary/environmental influence; levels stable across the lifespan
• Lp(a) has longer plasma residence time than LDL: apo(a) component (near LDLR binding site of apoB) interferes with LDLR docking → reduced LDLR-mediated clearance; requires alternative clearance pathways (kidney, SR-B1, plasminogen receptors)
• Statins upregulate LDLR numbers yet do not consistently lower Lp(a); PCSK9 inhibitors upregulate LDLR and do modestly reduce Lp(a) (~20–30%) — LDLR appears to have only a modest role in Lp(a) clearance
• Apo(a) LDL component derived from newly synthesised apoB-100, not from a VLDL precursor

Mechanisms of Lp(a)-Mediated CVD

• Lp(a) is more atherogenic per mol than LDL because it contains all proatherogenic components of LDL plus apo(a)-specific mechanisms
• Oxidized phospholipids (OxPL): OxPL are present in both the lipid phase and covalently bound to apo(a); Lp(a) is the primary carrier of OxPL in human plasma
• OxPL on Lp(a) → arterial wall inflammation (18-FDG PET arterial uptake); monocyte chemoattractant protein-1 (MCP-1) physically present on Lp(a); enhanced monocyte trafficking to arterial wall (confirmed with autologous radiolabeled monocytes); IL-8 release; inflammatory gene upregulation
• OxPL-apoB assay: primarily reflects OxPL content of Lp(a); performs as similar or superior predictor to Lp(a) mass for CVD and CAVS diagnosis/prognosis
• Lp(a) and OxPL highest in ruptured coronary plaques and carotid endarterectomy specimens (progressive accumulation as lesions advance)
• Antifibrinolytic potential: apo(a) competes with plasminogen for lysine-binding sites → potential inhibition of plasminogen activation to plasmin; however, clinical venous thrombosis studies could not link LPA SNPs to VTE (only factor V Leiden association); most patients with elevated Lp(a) are at risk primarily for atherosclerosis, not venous thrombosis

Lp(a) and CAVS

• LPA SNP rs10455872 is the only monogenic risk factor for aortic valve calcification and CAVS in multiple racial groups (GWAS of >2.5 million SNPs)
• Unifying mechanism: Lp(a) carries both autotaxin and OxPL into aortic valve leaflets → autotaxin converts lysophosphatidylcholine to lysophosphatidic acid → promotes inflammation, fibrosis, and procalcifying gene upregulation
• Autotaxin case-control (n=150 CAVS+CAD vs 150 CAD): autotaxin + Lp(a) >50 mg/dL → OR 3.46 for CAVS; autotaxin + OxPL-apoB >2.02 nM → OR 5.48 for CAVS
• ASTRONOMER Trial (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin):
  • Elevated Lp(a) >58.5 mg/dL AND OxPL-apoB >5.5 nM (3rd tertile) → peak AV jet velocity progression 0.26 ± 0.26 vs 0.17 ± 0.21 m/s/year (highest vs lowest tertile); AVR required in 20.4% overall
  • Younger patients (median <57 years) had nearly double the progression rate — consistent with genetically elevated Lp(a) as primary driver
  • Rosuvastatin: raised Lp(a) 20% and OxPL-apoB 46% in ASTRONOMER; rosuvastatin did not affect AS progression rate; confounding: LDL-C lowering benefit may offset Lp(a) raising effect

Clinical Epidemiology

• CardiogramPlus4D Consortium (63,746 CAD cases + 130,681 controls; GWAS of 46 loci): the LPA locus was numerically the most potent genetic association with CAD — more potent than LDL-related variants, PCSK9, and 9p21-related variants; this finding is underappreciated
• Meta-analysis (126,634 participants; 1.3 million person-years): curvilinear CVD risk starting to accelerate at Lp(a) >24 mg/dL; risk linear and more potent in genetic (Mendelian randomization) studies — ORs up to 4 in highest vs lowest Lp(a) quintile
• Bruneck Study (n=826; 15-yr follow-up; intermediate-risk individuals): Lp(a) reclassified 39.6% of intermediate-risk individuals into higher or lower risk categories when added to Framingham/Reynolds risk scores

Area of Controversy I: Assay Standardization

• Lp(a) measured in mg/dL (total particle mass — inherently limited by isoform heterogeneity; may overestimate large-isoform and underestimate small-isoform patients) or nmol/L (molar concentration — preferred; isoform-insensitive)
• Most clinical labs now linked to WHO/IFCC International Reference Reagent → relatively isoform-independent for clinical use

• 30 mg/dL or >75 nmol/L: US threshold for elevated; >50 mg/dL or >125 nmol/L: European threshold for elevated; >60 mg/dL: Germany/UK apheresis reimbursement threshold

• Lp(a) cholesterol gel-electrophoresis not validated — should not be used

Area of Controversy II: Risk Cut-offs

• EAS: <50 mg/dL optimal (20% of population at higher risk)
• Risk inflection in meta-analysis data at >24 mg/dL; Canadian CVS 2016: >30 mg/dL a risk factor
• 30% of global population (~2 billion people) have Lp(a) in atherogenic range
• CAVS risk data only available at >40–60 mg/dL

Area of Controversy IV: Once-Lifetime Measurement

• 90% genetically determined; stable over lifetime; single measurement sufficient for screening

• EAS 2010: once in all patients with premature CVD, intermediate/high risk, FH, FHx premature CVD; ESC/EAS 2016: Class IIa, Level C in selected high-risk cases

Area of Controversy V: Racial Differences

• Lp(a) levels: African descent > South Asian > Caucasian > Hispanic > East Asian
• Differences attributed to LPA gene migration patterns out of Africa
• ARIC (3,467 Black + 9,851 White; 20-yr follow-up): Lp(a) positively and similarly associated with CVD in both groups; elevated Lp(a) is an independent CVD risk factor in all racial groups studied

Area of Controversy VI: Residual Risk with Controlled LDL-C

• Lp(a) remains an independent risk factor even when LDL-C is well controlled — refutes earlier assumption that treating LDL-C negates Lp(a) risk
• AIM-HIGH: LDL-C 65.2 mg/dL + Lp(a) >125 nmol/L (≥75th percentile, ~50 mg/dL) → 89% higher MACE vs same LDL-C with low Lp(a)
• JUPITER: LDL-C 55 mg/dL + Lp(a) >54 nmol/L (~21 mg/dL) → 71% higher MACE
• LIPID: LDL-C ~112 mg/dL + Lp(a) >73.7 mg/dL → 23% higher MACE
• Pooled analysis (13,167 statin-treated patients): weighted HR 1.61 (LDL-C 89.1 mg/dL, Lp(a) 54.9 mg/dL)
• IMPROVE-IT: simvastatin/ezetimibe achieving LDL-C 54 mg/dL still had 32.7% recurrent MACE rate — suggests LDL-C-directed therapy alone insufficient

Area of Controversy VII: Do Statins Increase Lp(a)?

• Individual patient-level analysis of 3,896 patients (atorvastatin, pravastatin, rosuvastatin, pitavastatin, simvastatin/ezetimibe): mean patient-level Lp(a) increased +11% (up to +50% in some studies); OxPL-apoB increased +24%
• Mechanism unknown; may explain why some patients have inadequate LDL-C response to statins (most cholesterol on Lp(a) particles, which rise with statin therapy)
• Overall statin benefit is maintained, but patients with increased Lp(a) post-statin may derive less benefit than expected

Area of Controversy VIII: Current and Emerging Therapies

• No approved Lp(a)-specific therapy as of 2017
• Niacin: 19–39% Lp(a) reduction; AIM-HIGH baseline Lp(a) 13.5 mg/dL → reduced to 11 mg/dL (underpowered 4th-quartile analysis, ~700 pts; no event benefit)
• PCSK9 inhibitors: 20–30% reduction (limited populations)
• Mipomersen (apoB ASO): 25% Lp(a) reduction via apoB depletion; free apo(a) continues to be secreted
• Estrogen/progestin: 15–20% reduction; post hoc HERS benefit in 4th quartile only; not appropriate for atherothrombosis risk patients
• Apheresis: 30–35% time-averaged reduction; no randomised control group; Germany/UK reimburse for isolated Lp(a) >60 mg/dL + recurrent CVD
• CETP inhibitors: 20–30% reduction — insufficient per CETP inhibitor trial failures to show CV benefit
• Critical threshold insight: potential clinical benefit requires >50% mean Lp(a) reduction; CETP inhibitor failures at 20–30% support this hypothesis
• ASO to apo(a) (IONIS-APO[a]-LRx; GalNAc³-conjugated): selective hepatocyte uptake; mean reductions 66–92%, up to 99% in some patients; concurrent reduction in OxPL; first agent with plausible efficacy threshold; 3 Phase 1 RCTs showing dose-dependent reductions >80%

Area of Controversy IX: Proatherogenic vs. Prothrombotic

• Apo(a) competes with plasminogen for lysine binding → potential antifibrinolytic effect in vitro
• However, LPA SNPs and Lp(a) kringle repeats NOT associated with venous thromboembolism in clinical studies; factor V Leiden association present independently
• Elevated Lp(a) primarily increases atherosclerosis risk; thrombotic risk amplification may require a second underlying coagulation propensity
• Women's Health Study: women with elevated Lp(a) were the only subgroup to benefit from aspirin in this primary prevention trial — suggests antiplatelet therapy may attenuate Lp(a)-mediated vascular risk

Limitations of the Document

• 2017 review; pre-dates 2021 AHA Scientific Statement on Lp(a), ESC 2025, ACC/AHA 2026 lipid guidelines, and Phase 3 CVOT data for pelacarsen/olpasiran/zerlasiran
• Author has dual appointment at UCSD and Ionis Pharmaceuticals — potential conflict in framing ASO therapy favourably
• Statin–Lp(a) effect data (11% mean increase) not from RCTs but observational individual-patient analyses; later ESC 2025 states statins have no effect based on 7 placebo-controlled RCTs
• All cardiovascular outcome data for Lp(a) are post hoc or from Mendelian randomization — no dedicated prospective CVOT for Lp(a) lowering available at time of writing
• Risk cut-off controversy unresolved; >50% reduction hypothesis remains untested (Phase 3 CVOTs ongoing as of 2017)

Key Concepts Mentioned

• concepts/Lipoprotein-a — central subject; structure, mechanisms, risk quantification, controversies
• concepts/CAVD-Mechanisms — CAVS via OxPL and autotaxin pathway; ASTRONOMER data
• concepts/Dyslipidemia-Management — Lp(a) management in the context of overall lipid strategy
• concepts/ASCVD-Risk-Assessment — Lp(a) as independent residual risk factor

Key Entities Mentioned

• entities/Oxidized-Phospholipids — OxPL as primary mediator of Lp(a) atherogenicity

Wiki Pages Updated

• Created wiki/sources/lpa-jacc-2017.md
• Updated wiki/concepts/Lipoprotein-a.md (OxPL-apoB biomarker; ASTRONOMER data; AIM-HIGH/JUPITER/LIPID HR quantification; statin Lp(a) contradiction; >50% reduction threshold; racial hierarchy; Women's Health Study aspirin finding)
• Updated wiki/sourceindex.md
• Updated wiki/wikiindex.md